|
Darolutamide (Nubeqa®) 300 mg tablets Clinical Trials
2 actively recruiting trials across 1 location
Pipeline
Phase 1: 1
Top Sponsors
- ORIC Pharmaceuticals1
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS1
Indications
- Cancer2
- Castrate Sensitive Prostate Cancer1
- Metastatic Prostate Cancer1
- Metastatic Cancer1
- Prostate Cancer1
Other1 trial
Colorado Springs, Colorado1 trial
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Rocky Mountain Cancer Center
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.